stockrowHarmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.
- Revenue
- +12.3%
- EPS
- −6.24%
- Free cash flow
- −29.4%
- Total debt
- −11.5%
Quarter to September 2026, against a year earlier
Follow HRMY
Alert me
Harmony Biosciences Holdings, Inc. (HRMY) P/S ratio
As of 6 November 2026, Harmony Biosciences Holdings, Inc. (HRMY) trades at a P/S ratio of 2.0×. Over the past ten years it has ranged from 0.0× (December 2020) to 9.6× (March 2022); the current reading is higher than 10% of that period. That is below the Biotechnology industry median of 9.4× and below the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 2.5× | (9.55%) |
| FY2024 | 2.7× | (12.95%) |
| FY2023 | 3.1× | (56.04%) |
| FY2022 | 7.2× | (10.89%) |
| FY2021 | 8.0× | 37.71% |
| FY2020 | 5.8× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 2.3× | 5.47% |
| Jun 2026 | 2.2× | 22.00% |
| Mar 2026 | 1.8× | (27.29%) |
| Dec 2025 | 2.5× | 28.99% |
| 23 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| TRVI Trevi Therapeutics, Inc. compare | n/m |
| MAZE Maze Therapeutics, Inc. compare | n/m |
| TRAX First Tracks Biotherapeutics, Inc. compare | n/m |
| REPL Replimune Group, Inc. compare | n/m |
| FTRE Fortrea Holdings Inc. compare | 0.8× |
| SRPT Sarepta Therapeutics, Inc. compare | 1.0× |
| HRMY Harmony Biosciences Holdings, Inc. | 2.0× |
| VIR Vir Biotechnology, Inc. compare | 6.8× |
| MESO Mesoblast Limited compare | 148× |
| Biotechnology industry median | 9.4× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)